Development of a rapid fluorescence-based high-throughput screening assay to identify novel kynurenine 3-monooxygenase inhibitor scaffolds

K. R. Jacobs, G. J. Guillemin, D. B. Lovejoy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Kynurenine 3-monooxygenase (KMO) is a well-validated therapeutic target for the treatment of neurodegenerative diseases, including Alzheimer's disease (AD) and Huntington's disease (HD). This work reports a facile fluorescence-based KMO assay optimized for high-throughput screening (HTS) that achieves a throughput approximately 20-fold higher than the fastest KMO assay currently reported. The screen was run with excellent performance (average Z' value of 0.80) from 110,000 compounds across 341 plates and exceeded all statistical parameters used to describe a robust HTS assay. A subset of molecules was selected for validation by ultra-high-performance liquid chromatography, resulting in the confirmation of a novel hit with an IC50 comparable to that of the well-described KMO inhibitor Ro-61-8048. A medicinal chemistry program is currently underway to further develop our novel KMO inhibitor scaffolds.
Original languageEnglish
Pages (from-to)554-560
Number of pages7
JournalSLAS Discovery
Volume23
Issue number6
Early online date8 Feb 2018
DOIs
Publication statusPublished - 1 Jul 2018

Keywords

  • kynurenine 3-monooxygenase
  • high-throughput screening
  • kynurenine
  • 3-hydroxykynurenine
  • neurodegeneration
  • NADPH fluorescence

Fingerprint Dive into the research topics of 'Development of a rapid fluorescence-based high-throughput screening assay to identify novel kynurenine 3-monooxygenase inhibitor scaffolds'. Together they form a unique fingerprint.

Cite this